Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8+ T cells in patients with myeloid malignancies
Open Access
- 17 February 2010
- journal article
- Published by Wiley in Cancer Science
- Vol. 101 (3) , 594-600
- https://doi.org/10.1111/j.1349-7006.2009.01453.x
Abstract
(Cancer Sci 2010; 101: 594–600) WT1 (Wilms’ tumor gene 1) protein is a potent pan‐tumor‐associated antigen (TAA) and WT1‐specific cytotoxic T lymphocytes (WT1 tetramer+ CD8+ T cells) are spontaneously induced in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a single‐cell level comparative analysis of T‐cell receptor β‐chain variable region (TCR‐BV) gene families of a total of 1242 spontaneously induced WT1 tetramer+ CD8+ T cells in HLA‐A*2402+ patients with AML or MDS and those in healthy donors (HDs). This is the first report of direct usage analysis of TCR‐BV gene families of individual TAA‐specific CD8+ T cells at single‐cell level. Usage analysis using single‐cell RT‐PCR of TCR‐BV gene families of individual FACS‐sorted WT1 tetramer+ CD8+ T cells showed for the first time (i) that BVs 5, 6, 20, and 27 were commonly biased in both HDs and patients; (ii) that BV4 was commonly biased in HDs and MDS patients; (iii) that BV19 was commonly biased in the patients; and (iv) that BVs 7 and 28, BVs 9 and 15, and BVs 12 and 29 were specifically biased in HDs, AML, and MDS patients, respectively. However, statistical analysis of similarity among HD, AML, and MDS of individual usage frequencies of 24 kinds of TCR‐BV gene families indicated that the usage frequencies of TCR‐BV gene families in AML and MDS patients reflect those in HDs. These findings represent a novel insight for a better understanding of WT1‐specific immune response.This publication has 36 references indexed in Scilit:
- A Highly Restricted T-Cell Receptor Dominates the CD8+T-Cell Response to Parvovirus B19 Infection in HLA-A*2402-Positive IndividualsJournal of Virology, 2006
- Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA virusesThe Journal of Experimental Medicine, 2005
- Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignanciesLeukemia, 2004
- T‐cell receptor Vβ gene usage by T cells reactive with the tumor‐rejection antigen SART‐1 in oral squamous cell carcinomaInternational Journal of Cancer, 2003
- Improved Assessment of T-Cell Receptor (TCR) VB Repertoire in Clinical Specimens: Combination of TCR-CDR3 Spectratyping with Flow Cytometry-Based TCR VB Frequency AnalysisClinical and Vaccine Immunology, 2002
- Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell GrowthJapanese Journal of Cancer Research, 1999
- Human leukocyte antigen phenotype imposes complex constraints on the antigen‐specific cytotoxic T lymphocyte repertoireEuropean Journal of Immunology, 1997
- T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.The Journal of Experimental Medicine, 1993
- Population study of T cell receptor Vβ gene usage in peripheral blood lymphocytes: differences in ethnic groupsClinical and Experimental Immunology, 1993
- Repression of the Insulin-Like Growth Factor II Gene by the Wilms Tumor Suppressor WT1Science, 1992